Clinical Trials Search at Vanderbilt-Ingram Cancer Center

A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or ALK Inhibitor Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL) (IND# 134379)

Disease Sites:

Not Available

Staging:

Phase III

Age Group:

Both

Therapies:

Not Available

Drugs:

Not Available

Principal Investigator(s):

Not Available

Scope:

National

Participating Institutions:

Vanderbilt University

Open Date:

09-17-2018

Trial Type:

Treatment

Protocol ID:

COGANBL1531

National Clinical Trial ID:

NCT03126916

Related Internal Documents:

View Internal Documents

Eligibility

Ages Eligible for Study:

Not Available

Genders Eligible for Study:

Not Available

Accepts Healthy Volunteers?:

Not Available